tbuckley/cabot-search huggingface dataset:
Slower B16 Melanoma Growth but Greater Pulmonary Colonization in Calorie-Restricted Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: W B Ershler, E Berman, A L Moore
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Slower B16 Melanoma Growth but Greater Pulmonary Colonization in Calorie-Restricted Mice Get access William B. Ershler, William B. Ershler 4 4Address reprint requests to Dr. Ershler at his present address: Department of Medicine, University of Wisconsin, 2580 Medical Sciences Center, 1300 University Ave., Madison, WI 53706. Search for other works by this author on: Oxford Academic PubMed Google Scholar Eve Berman, Eve Berman Search for other works by this author on: Oxford Academic PubMed Google Scholar Ann L. Moore Ann L. Moore Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 1, January 1986, Pages 81–85, https://doi.org/10.1093/jnci/76.1.81 Published: 01 January 1986 Article history Received: 12 March 1985 Accepted: 23 September 1985 Published: 01 January 1986
Patient out-of-pocket and insurer payment decisions for bevacizumab for metastatic colorectal cancer: A Canadian analysis
Authors: S. Yunger, P. Douglas, P. Anglin, M. Crump, S. Lepage, D. Shum, L. Phillips, D. Milliken
Journal: Journal of Clinical Oncology (2009)

6576 Background: Like many health care services in Canada, intravenous (IV) cancer therapies are typically funded publicly through hospitals and provincial cancer agencies. Delays may be encountered between regulatory approval and public funding of new drugs. IV drugs are not routinely covered through private insurance (PRI) plans, requiring patients to appeal for special consideration, including employer exceptions or pay cash. Uncertainty of drug funding may create challenges for physicians and patients when discussing treatment options. The Roche Patient Assistance Program (RPAP) provides reimbursement navigation, copay/financial assistance and access to infusion clinics. This observational study examines patient access to bevacizumab (B) in the absence of public funding. Methods: An analysis of the RPAP database for the period of July 2006 to August 2008 was conducted assessing patients enrolled, insurance status, approval rates, and access to B. Receipt of treatment with B was evaluated according to insurance coverage. Results: A total of 877 patients accessed the RPAP for treatment with B. 647 (74%) had PRI and 230 (26%) were uninsured. Of PRI patients, 310 (48%) were approved coverage and 337 (52%) were denied. 204 patients (65%) with approved PRI coverage received B therapy. Of patients with PRI but denied coverage for B, 135 (40%) elected to pay for B. Of patients with no PRI, 120 (52%) paid for B. Of all patients with no coverage for B (no PRI or denied PRI), 255 patients (45%) elected to pay for B. Conclusions: In a public healthcare environment, when B was not publicly funded, approximately half of patients without any PRI coverage who accessed the RPAP were willing to pay for B. Although private insurers state IV drugs are not plan benefits, almost half of patients were able to obtain B coverage. A conventional analysis of willingness-to-pay should be conducted to better understand reasons behind patient and private insurer decisions observed in this study. Further research should also be conducted to determine whether results can be generalized to other unfunded anticancer agents within the Canadian health care system. [Table: see text]
<i>Pomegranate Jars</i>
Authors: M. Therese Southgate
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A comparison of national and in-house examinations of psychiatric knowledge
Authors: G D Strauss, J Yager, E H Liston
Journal: American Journal of Psychiatry (1984)

The search continues for the optimum method of assessing psychiatric residents' knowledge. In 1982, 72% of the U.S. residency programs gave the Psychiatry Resident In-Training Examination ( PRITE ). The authors compared the PRITE with an examination developed by their program. The two tests yielded highly correlated percentages of correct responses and resident rank orders for advanced residents, detected similar areas of weakness, had comparable dollar costs, and elicited similar, moderately high resident satisfaction. Important differences were the amount of information and feedback provided to residents and to the residency program and the time between the test and the feedback.
The human myeloid cell nuclear differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q that are expressed specifically in hematopoietic cells
Authors: RC Briggs, JA Briggs, J Ozer, L Sealy, LL Dworkin, SF Kingsmore, MF Seldin, GP Kaur, RS Athwal, EN Dessypris
Journal: Blood (1994)
Ratio of inhaled corticosteroid to bronchodilator as indicator of quality of asthma prescribing
Authors: S. J Roberts, J H Baumer, C. J Currie, M. Evans, C. L Morgan, C. Griffiths, P. Sturdy, J. Naish, G. Feder, R. Omar, S. Dolan, F. Pereira, M. Shelley, P. Croft, C. Pantin, S. Chapman
Journal: BMJ (1997)
Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis
Authors: Jennifer Ho, Phuong Thi Bich Nguyen, Thu Anh Nguyen, Khoa Hien Tran, Son Van Nguyen, Nhung Viet Nguyen, Hoa Binh Nguyen, Khanh Boi Luu, Greg J Fox, Guy B Marks
Journal: The Lancet Infectious Diseases (2016)
Quality assurance for the diagnostics of viral diseases to enhance the emergency preparedness in Europe
Authors: O Donoso-Mantke, H Schmitz, H Zeller, P Heyman, A Papa, M Niedrig
Journal: Eurosurveillance (2005)

The threat posed by emerging and re-emerging communicable diseases and, more recently, by the intentional release of infectious agents in a susceptible population, has been receiving considerable attention at the national and international levels. Public health efforts to strengthen disease detection, surveillance and control have been intensified. However, clinicians and clinical microbiology laboratories play an important role in the early detection of disease, the identification of the putative agent, and notification of the appropriate authorities. To be effective in this role, laboratories must be specially prepared to handle viral agents safely, and need, among other things, the appropriate rapid and sensitive diagnostic tests. In 1998 the European Network for Diagnostics of “Imported” Viral Diseases (ENIVD) was established. ENIVD presently comprises, as permanent members, 44 expert laboratories in 21 European Union (EU) member states and 4 non-EU countries and is one of the networks on infectious diseases funded by the European Commission. ENIVD fulfils many of the important tasks required for the surveillance and control of imported, rare and emerging viral infections such as the exchange of expertise and the organisation of external quality assurance (EQA) programmes, both of which are needed to improve diagnostics. Here, we summarise the data generated by recent EQA activities focussed on the diagnostics of infections with hantavirus, dengue virus, filovirus, Lassa virus, orthopox virus and the SARS-coronavirus (SARS-CoV). These were carried out between 1999 and 2004 and involved 93 laboratories from 41 countries, including laboratories from additional countries outside of Europe. Particularly the EU-candidate countries and Eastern neighbouring countries will be invited to join the network in the near future. A public website is available at http://www.enivd.de.
THU0560 Atherosclerosis in Behçet Disease: A Systematic Review &amp; Metanalysis
Authors: M. Merashli, I. Chis Ster, P. RJ Ames
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Behçet9s disease is a systemic vasculitis characterised by an elevated risk of venous and arterial thrombosis: several studies addressed the issue of premature atherosclerosis assessed by functional tests (flow and endothelial mediated vasodilatation: FMD/EMD) and measurement of intima media thickness (IMT) of carotid arteries with varied results. <h3>Objectives</h3> To perform a systematic review and meta-analysis on the association between Behçet9 disease (BD) and atherosclerosis detected as endothelial dysfunction (FMD &amp; EMD) and IMT of carotid arteries. <h3>Methods</h3> The EmBase and PubMed databases were systematically searched from January 2000 to January 2014 according to the PRISMA guidelines. Two authors independently extracted data by using predefined eligibility criteria. <h3>Results</h3> We found 24 studies that met criteria for inclusion in our analysis, 9 on FMD/EMD, 11 on IMT and 4 on both. The FMD analysis involved 554 BD patients and 472 matched controls: FMD was impaired in BD but with a high estimate (SMD 1.841, 95% CI, 1.125-2.558, p&lt;0.001, I<sup>2</sup>=95.6%); subgroup analysis on inactive patients confirmed impaired FMD with a valid estimate (SMD 0.740, 95% CI, 0.510-0.970, I<sup>2</sup> =35.5%). The EMD analysis involved 360 BD patients and 306 matched controls: EMD was impaired but with a large estimate (SMD 0.380, 95% CI, -0.027-0.788, p=0.06, I<sup>2</sup>=82.2%); subgroup analysis was unrevealing. The IMT analysis involved 848 patients with BD and 677 controls: BD patients showed greater IMT than controls but with a large estimate (SMD -1.158, 95%CI, -0.522 to -0.793, p&lt;0.0001, I<sup>2</sup>=88.4%); subgroup analysis on active then on inactive patients still revealed a large estimate (I<sup>2</sup>=88.4% and 86.7% respectively), even when BD with no vascular involvement and no cardiovascular risk factor were excluded from the analysis (I<sup>2</sup>=85.9%). By re-approached the IMT analysis according to the Newcastle Ottawa Quality Assessment Score (NOQAS), studies with a NOQAS of 5 were consistent with greater IMT in BD with valid estimate (SMD -1.720, 95% CI, -2.093 to -1.346, p&lt;0.0001, I<sup>2</sup>=48.6%); similar data were seen for BD patients with a NOQAS 6/7 (SMD -0.537, 95% CI, -0.753 to-0.320 p&lt;0.05, I<sup>2</sup>=58.7%). <h3>Conclusions</h3> Atherosclerosis detected by FMD and IMT is present in BD: the moderate degree of statistical heterogeneity reflects in the clinical heterogeneity of BD that should be taken into account in future prospective studies. <h3>References</h3> Subclinical Atherosclerosis in Behçet9s disease: An overlooked association. Saarbrücken Germany, LAP LAMBERT Academic Publishing, 2013. <h3>Disclosure of Interest</h3> None declared
Prevalence Of FLT3 Mutations In Acute Myeloid Leukemia: A Multicenter Latin America Study
Authors: Jorge Cuervo-Sierra, David Gómez-Almaguer, Jose Carlos Jaime-Pérez, Ramón Alejandro Martínez-Hernández, Ricardo David García Sepúlveda, Mónica Sánchez-Cárdenas, Rocio Ortiz-López, Gregorio Ignacio-Ibarra, Gabriel Muciño-Hernández, Rosa Maria Arana-Trejo, Guillermo J. Ruiz-Arguelles, Guillermo J. Ruiz-Delgado, Julia Lutz-Prestno, Angélica Jiménez-Mejía, Gonzalo Vásquez-Palacio, Mauricio Camargo-Guerrero
Journal: Blood (2013)
THE PROBLEM OF PSYCHIATRIC NOSOLOGY
Authors: THOMAS S. SZASZ
Journal: American Journal of Psychiatry (1957)

The thesis of this essay is that most problems of psychiatric nosology, as currently formulated, are refractory to solution because of certain basic ambiguities in psychiatric concepts and operations. Scientific clarity and progress in this area depend upon clear agreement on the following issues: 1. The scope and subject matter that is to be designated as "psychiatry" (e.g., brain, mind, or behavior); 2. The scientific and technical methods that characterize this branch of knowledge (e.g., physics or psychology, physico-chemical techniques or psychotherapy); 3. The precise nature of the phenomena that we seek to classify (e.g., physical or chemical changes in the brain, social behavior, or behavior toward specific individuals). These are not three separate categories, but represent rather interlocking aspects of what must be, in the last analysis, operational descriptions of specific "psychiatric situations." It is suggested that we distinguish sharply between the following principal psychiatric situations on the current American scene: the mental hospital, private psychiatric practice (including the psychoanalytic situation), the child guidance clinic, the psychoanalytic training system, military service, the court of law and jail. Illustrative samples of an operational analysis of a few of these situations are presented. A similar scrutiny of the psychiatric situations that characterized the work of each of the principal figures in the history of psychiatry since Kraepelin is suggested and briefly sketched. This mode of approach prompts one to take a more "relativistic" view of psychiatry, by which is meant the appreciation that different observational methods imply differences in the very nature of the observed "material." Thus, global approaches to psychiatry may have to be abandoned in favor of more limited, and socially and methodologically better defined, plans of attack on specific problems. It is further inherent in this line of thought that a nosological system developed in, and appropriate to, one type of psychiatric situation cannot be validly transferred to another, radically different psychiatric situation. This is a principle familiar to us from other branches of science and technology and the various systems of classification that they employ. Considerations of nosology also prompt a scrutiny of the specific items that are classified. At present, probably the single most important diagnostic label in psychiatry is "schizophrenia." Some epistemological aspects of the problem of schizophrenia are briefly discussed, and it is suggested that this word may now function as a "panchreston" ( or "explain-all") which, instead of illuminating, obscures the essential problems that face psychiatry today. In conclusion, some observations are offered on the currently widespread disregard of nosological rules by psychiatrists and its inhibiting influence on progress in psychiatry.
FRI0573 Sensitivity of Metacarpal Bone Loss in the Detection of Rheumatoid Arthritis
Authors: A. Pfeil, J. Böttcher, D. Renz, P. Oelzner, G. Wolf
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Digital X-ray Radiogrammetry (DXR) is a computer based technique to quantify cortical hand bone mineral density (BMD) as well as metacarpal index (MCI) at the metacarpal bones from radiographs in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> The objective was to compare DXR-BMD and DXR-MCI between healthy individuals and patients with RA and verify the sensitivity and specificity of this technique for the identification of cortical hand bone loss as an additional diagnostic approach in RA. <h3>Methods</h3> In total, 976 patients were enrolled and divided into two groups; those with RA (n=333) and a healthy control group (n=643) as a reference data base. Bone DXR-BMD and the DXR-MCI were measured by DXR using hand radiographs. Severity of RA was evaluated by the modified Larsen Score. <h3>Results</h3> The mean values for DXR-BMD and DXR-MCI in RA patients were significantly lower compared to the healthy subjects (23.7% and 22.7%). Depending on the severity of joint damage RA, DXR-BMD revealed a significant reduction of –27.9% and DXR-MCI –28.3%, comparing score 1 and Score 5 of the modified Larsen Score. Both DXR-BMD and DXR-MCI had a high sensitivity (DXR-BMD 95%; DXR-MCI 92%) and moderate specificity (DXR-BMD 48%, DXR-MCI 51%) to identify RA related cortical hand bone loss. <h3>Conclusions</h3> The DXR-technique is able to quantify RA-related periarticular bone loss as a typical feature in the course of RA. Consequently, in this case periarticular osteoporosis seems to function as a reliable diagnostic approach comparable to erosions and joint space narrowing in the diagnosis of RA and as a surrogate marker for the progression of bone damage in RA. <h3>Disclosure of Interest</h3> None declared
Cigarette Smoking Among Urban American Indian Adults — Hennepin and Ramsey Counties, Minnesota, 2011
Authors: Jean Forster, John Poupart, Kristine Rhodes, Melanie Peterson-Hickey, Genelle Lamont, Joanne D’Silva, Darin Erickson
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In 2013, it was estimated that the prevalence of cigarette smoking among American Indians was 36.5%, the highest of all racial/ethnic groups in the continental United States (1). Among American Indians, considerable cultural and geographic variation in cigarette smoking exists. Smoking prevalence among American Indians is lowest in the Southwest and highest in the Upper Midwest/Northern Plains (2). Little information is available about tobacco use among urban American Indians, who might not have ever lived on a reservation or be enrolled in or affiliated with a tribe. In Minnesota, a significant proportion of American Indians reside in urban areas. Among Minnesota's residents who identify as American Indian alone or in combination with another race, 30% live in Hennepin County and Ramsey County, which encompass Minneapolis and St. Paul, respectively (collectively known as the Twin Cities). The predominant tribes (Ojibwe [Chippewa] and Dakota/Lakota/Nakota [Sioux]) traditionally have used locally grown tobacco (Nicotiana rustica), red willow, and other plants for religious ceremonies, although nonceremonial tobacco is often substituted for traditional plants. To assess prevalence of cigarette smoking among this population, it is important to distinguish ceremonial tobacco use (smoked or used in other ways) from nonceremonial tobacco use. To obtain estimates of cigarette smoking prevalence among American Indians in Hennepin and Ramsey counties, the American Indian Adult Tobacco Survey was administered to 964 American Indian residents in 2011, using respondent-driven sampling. Among all participants, 59% were current smokers, 19% were former smokers, and 22% had never smoked. Approximately 40% of employed participants reported that someone smoked in their workplace area during the preceding week. High prevalences of cigarette smoking and secondhand smoke exposure among urban American Indians in Minnesota underscores the need for a comprehensive and culturally appropriate approach to reducing nonceremonial tobacco use.
The DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
Authors: U Schlegel
Journal: New England Journal of Medicine (2001)

To the Editor: Esteller and colleagues (Nov.9 issue) 1 claim that methylation of the O 6 -methylguanine-DNA methyltransferase ( MGMT ) promoter is associated with improved responsiveness to carmustine and prolonged survival in patients with high-grade gliomas.We believe there are methodologic flaws in the authors' study that call these results into question.First, the patients in the study were treated with a combination of surgery, radiation therapy, and chemotherapy with cisplatin and carmustine.We do not believe the response to carmustine is a discernible end point in this trial, because multiple treatments were administered along with carmustine.Second, although the difference in age between the group of patients with unmethylated tumors and the group with methylated tumors was not statistically different, there was a trend toward an older age in the group with unmethylated tumors.We are not given the distribution of ages above or below 50 years.Since the prognosis worsens with each additional decade of age, such information would be useful in assessing the balance in age between the two groups. 2,3 Third, the median period of survival was approximately 20 months for the patients with unmethylated tumors and approximately 30 months for those with methylated tumors, as compared with an average of about 12 months in other series. 2,3 Moreover, since no deaths occurred before 12 months, it is unlikely that the patients chosen for this study were representative of most patients with the disease.Finally, the small numbers of deaths in the two groups of patients make the results of a statistical comparison questionable.
Qualitative Changes in the Biologic Characteristics of Cultured Fetal Rat Keratinizing Epidermal Cells During the Process of Malignant Transformation After Benzo[&lt;italic&gt;a&lt;/italic&gt;]pyrene Treatment&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: K Indo, H Miyaji
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Qualitative Changes in the Biologic Characteristics of Cultured Fetal Rat Keratinizing Epidermal Cells During the Process of Malignant Transformation After Benzo[a]pyrene Treatment Get access Katsuhiko Indo, Katsuhiko Indo Search for other works by this author on: Oxford Academic PubMed Google Scholar Hideki Miyaji Hideki Miyaji Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 63, Issue 4, October 1979, Pages 1017–1027, https://doi.org/10.1093/jnci/63.4.1017 Published: 01 October 1979 Article history Received: 27 October 1978 Accepted: 06 April 1979 Published: 01 October 1979
Increased incidence of Mycoplasma pneumoniae infection in England and Wales in 2010: multiocus variable number tandem repeat analysis typing and macrolide susceptibility
Authors: V J Chalker, T Stocki, M Mentasti, D Fleming, T  G Harrison
Journal: Eurosurveillance (2011)

An epidemic of Mycoplasma pneumoniae infection began in Denmark in late 2010. A similar increase in M. pneumoniae infections was noted in England and Wales in the same period, with a decline in early 2011. Multiocus variable number tandem repeat analysis typing and analysis of macrolide resistance markers indicate that at least nine known and two novel strain types were circulating in England and Wales during October 2010 to January 2011. There was no evidence of macrolide resistance.